Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Advanced Research Inc

Neither a doctor nor a teaching hospital

Research payments

$4,746,417

393 payments

Through program year 2025, Advanced Research Inc is reported as receiving $4,746,417 in research payments, across 393 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $2,399,172 143
2024 Research $1,027,629 92
2023 Research $408,298 42
2022 Research $125,851 23
2021 Research $42,513 8
2020 Research $105,287 33
2019 Research $637,668 52

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $1,668,617 53 payments
  2. AbbVie, Inc. $1,064,714 77 payments
  3. Sanofi US Services Inc. $846,397 40 payments
  4. Allergan Inc. $486,164 50 payments
  5. Teva Pharmaceuticals USA, Inc. $282,107 101 payments
  6. Braintree Laboratories, Inc. $107,515 2 payments
  7. Phathom Pharmaceuticals, Inc. $60,347 10 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $39,023 11 payments
  9. AstraZeneca Pharmaceuticals LP $37,736 3 payments
  10. Urovant Sciences Inc $37,512 10 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet $759,103 31 payments
  2. A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants $614,160 17 payments
  3. A Study of Retatrutide (Ly3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity Or Overweight (Triumph-2) $411,365 4 payments
  4. A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants With Hypertension and Obesity Or Overweight: Randomized, Double-Blind, Placebo-Controlled Trials (Attain-Hypertension). Isas-Gzl1;Gzl2 $352,558 4 payments
  5. Multicenter Double Masked Randomized Vehicle-Controlled Parallel-Group study of AGN-190584 for Participants with Presbyopia $274,478 10 payments
  6. A Phase 3 Randomized Double-Blind Placebo-Controlled Study to Investigate the Effect of Tirzepatide on the Reduction of Morbidity and Mortality in Adults With Obesity $165,644 7 payments
  7. Tv53408-Imm-10197 $160,576 70 payments
  8. A Master Protocol to Investigate the Efficacy and Safety of Ly3437943 Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity Or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (Triumph-1) $158,651 4 payments
  9. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Tirzepatide on the Reduction of Morbidity and Mortality in Adults With Obesity $152,002 7 payments
  10. A Study of Retatrutide (Ly3437943) in Participants Who Have Obesity Or Overweight (Triumph-1) $151,090 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record